Identification of HYIpro-3-1 Metabolites, a Novel Anti-Inflammatory Compound, in Human Liver Microsomes by Quadrupole-Orbitrap High-Resolution Mass Spectrometry
Mass Spectrometry Letters / Mass Spectrometry Letters, (P)2233-4203; (E)2093-8950
2021, v.12 no.4, pp.172-178
https://doi.org/10.5478/MSL.2021.12.4.172
Bai Honghao
(Kyungpook National University)
Kim Younah
(Kyungpook National University)
Paudel Sanjita
(Kyungpook National University)
Lee Eung-Seok
(Yeungnam University)
Lee Sangkyu
(Kyungpook National University)
Bai,
H., Kim,
Y., Paudel,
S., Lee,
E., &
Lee,
S.
(2021). Identification of HYIpro-3-1 Metabolites, a Novel Anti-Inflammatory Compound, in Human Liver Microsomes by Quadrupole-Orbitrap High-Resolution Mass Spectrometry. Mass Spectrometry Letters, 12(4), 172-178, https://doi.org/10.5478/MSL.2021.12.4.172
Abstract
HYIpro-3-1 is an adjuvant for preventing or treating inflammatory growth diseases. In this study, we identified the
metabolic pathway of HYIpro-3-1 in human liver microsomes (HLMs) by quadrupole-orbitrap high-resolution mass
spectrometry (HR-MS) and characterized the major human cytochrome P450 (CYP). Ten metabolites were identified, including one O-demethylation (M1), two O-demethylation and monohydroxylation (M2 and M3), and seven monohydroxylation metabolites (M4–M10). Based on the HR-MS 2 spectra, the metabolites are divided into two groups of monohydroxylated metabolites according to the hydroxylation position. We verified that HYIpro-3-1 is metabolized by CYP in HLMs, CYP2B6 is mainly involved in O-demethylation, and various CYPs are involved in the monohydroxylation of HYIpro-3-1.
- keywords
-
HYIpro-3-1,
LC-HR/MS,
cytochrome P450,
human liver microsomes
- Submission Date
- 2021-10-13
- Revised Date
- 2021-11-23
- Accepted Date
- 2021-11-24